Pharma channel feed

Sanofi teams with non-prof­it on a land­mark new drug for sleep­ing sick­ness

7 years ago
R&D
Discovery

Unit­ed Ther­a­peu­tics pays $800M-plus to grab Are­na’s PhI­II PAH drug

7 years ago

Ab­b­Vie en­lists pro­tein degra­da­tion ex­perts at Mis­sion for a new bet on Alzheimer's, Parkin­son's

7 years ago

What's com­ing? Paz­dur, Marks and Wood­cock dis­cuss FDA changes

7 years ago

FDA press­es its cam­paign against rogue re­gen­er­a­tive med play­ers, cites Stem­Genex for il­le­gal sales

7 years ago
Cell/Gene Tx

Cel­gene dou­bles down on Drag­on­fly­'s nat­ur­al killer tech, ex­pand­ing in­to sol­id tu­mors with an in­jec­tion of 'am­pli­fi­ca­tion cap­i­tal'

7 years ago

South Ko­re­an reg­u­la­tor sus­pends Sam­sung Bi­o­Log­ic­s' stock, cit­ing ac­count­ing vi­o­la­tions

7 years ago
R&D

Nestlé ups its bet on Aim­mune’s peanut al­ler­gy drug to $276M as NDA fil­ing looms, ri­val­ry in­ten­si­fies

7 years ago

FDA looks to strength­en ex­pand­ed ac­cess pro­gram

7 years ago

Genen­tech de­tails claims Sanofi part­ner JHL used stolen trade se­crets to de­vel­op ri­val drugs at an 'as­ton­ish­ing pace'

7 years ago
R&D

Ab­b­Vie hatch­es plans for a ma­jor new R&D hub close to its part­ners in Bay Area's buzzy Oys­ter Point

7 years ago
R&D

Drug­mak­ers seek clar­i­ty on guid­ance on use of place­bo and blind­ing in on­col­o­gy tri­als

7 years ago

As­traZeneca chief Pas­cal So­ri­ot her­alds the start of a 'pe­ri­od of sus­tained growth for years to come'

7 years ago

Bris­tol-My­ers lays off the last 63 staffers at Zy­mo­Ge­net­ics, shut­ters Seat­tle op­er­a­tions

7 years ago

With its back against the wall, Reg­u­lus hands over its lead mi­croR­NA drug to Sanofi for a small down pay­ment

7 years ago

Go­ing gang­busters in atopic der­mati­tis, the FDA hands Sanofi and Re­gen­eron a fresh coup for their mega-block­buster star Dupix­ent

7 years ago

Bar­gain sale con­tin­ues: As­traZeneca of­floads three res­pi­ra­to­ry drugs to Co­vis in $350M deal

7 years ago

Af­ter play­ing pos­sum in I/O, Eli Lil­ly shows new signs of life with $40M-plus cash dis­cov­ery deal for NextCure

7 years ago

Stick­er shock: No­var­tis says its top drug prospect is worth $4M-$5M for a once-and-done use

7 years ago

Need al­ter­na­tive fund­ing chan­nels? Per­cep­tive Ad­vi­sors now has $675M de­vot­ed to those deals

7 years ago

In an­oth­er try at lung can­cer niche, J&J nabs a po­ten­tial Tagris­so ri­val for $50M-plus

7 years ago
R&D

Co­herus looks to dis­rupt Am­gen’s $4B Neu­las­ta fran­chise as an­a­lysts look for a deep dis­count on its copy­cat price

7 years ago

Sage ap­pears set for a break­through FDA OK on post­par­tum de­pres­sion drug, but who’s go­ing to use it?

7 years ago

Tripped up by the FDA, No­var­tis says it is drop­ping out of the US race to win an OK for a block­buster Rit­ux­an ri­val

7 years ago
R&D
First page Previous page 283284285286287288289 Next page Last page
A service from the Financial Times